Grifols (GIFLF) Short term Debt (2009 - 2024)
Grifols' (GIFLF) quarterly Short term Debt came in at $722.5 million in Q4 2024, down 34.4% on a YoY basis from $1.1 billion in Q1 2024, and down 34.4% quarter-over-quarter from $1.1 billion in Q4 2023.
Analysis
Grifols (GIFLF) Short term Debt (2009 - 2024) Analysis & Trends
Grifols (GIFLF) has reported Short term Debt for 16 consecutive years, with $722.5 million the latest figure, recorded in Q4 2024.
- For the quarter ending Q4 2024, Short term Debt fell 34.4% year-over-year to $722.5 million; the trailing twelve-month figure through Dec 2024 stood at $722.5 million (down 34.4% YoY), and the FY2024 full-year result was $722.5 million, down 34.4% from the prior year.
- Short term Debt eased to $722.5 million in Q4 2024 per GIFLF's latest filing, from $1.1 billion in the prior quarter.
- Across five years, Short term Debt topped out at $2.8 billion in Q4 2021 and bottomed at $365.9 million in Q1 2020.
- Historically, Short term Debt has averaged $953.0 million across 5 years, with a median of $722.5 million in 2024.
- The sharpest annual moves came in 2021 and 2022: Short term Debt surged 450.97% in 2021, then slumped 70.9% in 2022.
- Over 5 years, Short term Debt stood at $506.3 million in 2020, then surged by 450.97% to $2.8 billion in 2021, then plunged by 70.9% to $811.8 million in 2022, then surged by 35.67% to $1.1 billion in 2023, then plunged by 34.4% to $722.5 million in 2024.
- According to Business Quant data, Short term Debt over the past three periods registered $722.5 million, $1.1 billion, and $811.8 million for Q4 2024, Q4 2023, and Q4 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 722.46 Mn |
| Dec 31, 2023 | 1.10 Bn |
| Dec 31, 2022 | 811.80 Mn |
| Dec 31, 2021 | 2.79 Bn |
| Dec 31, 2020 | 506.26 Mn |
| Sep 30, 2020 | 373.69 Mn |
| Mar 31, 2020 | 365.85 Mn |
| Dec 31, 2019 | 399.93 Mn |
| Sep 30, 2019 | 462.26 Mn |
| Dec 31, 2018 | 316.60 Mn |
| Sep 30, 2018 | 287.95 Mn |
| Jun 30, 2018 | 244.77 Mn |
| Mar 31, 2018 | 405.38 Mn |
| Dec 31, 2017 | 182.58 Mn |
| Jun 30, 2017 | 163.35 Mn |
| Dec 31, 2016 | 248.41 Mn |
| Sep 30, 2016 | 248.78 Mn |
| Jun 30, 2016 | 243.09 Mn |
| Mar 31, 2016 | 15.11 Mn |
| Dec 31, 2015 | 287.73 Mn |